From Yahoo Finance: 2025-06-11 11:27:00

Pfizer Inc. (NYSE: PFE) is among the best wide moat stocks to buy now. CEO Albert Bourla met with Trump administration to discuss reducing US drug prices, but no commitments were made. Trump’s order aims to align US drug prices with those in other high-income countries to lower costs for American patients.

Bourla expressed uncertainty about the government’s plan to lower drug prices and hinted at possible repercussions on global drug pricing. Pfizer focuses on heart health, infectious diseases, migraines, immune disorders, and cancer treatments. The company may withhold drugs from government reimbursement in countries not increasing prices to match the US.

Pfizer’s CEO remains optimistic about the company’s position amid potential changes in drug pricing policies. Analysts and legal professionals anticipate challenges in executing the new pricing strategy. Health Secretary Robert F. Kennedy, Jr. plans to launch a system allowing American patients to purchase drugs at a “Most-Favored-Nation” price directly from manufacturers.

Read more: Pfizer CEO Mentioned No Drug Price Commitments by Pfizer Inc. (PFE)